Project 2: Leveraging Metagenomics of the Microbiome to predict colonization/infection by antimicrobial-resistant pathogens

项目 2:利用微生物组的宏基因组学来预测耐药病原体的定植/感染

基本信息

项目摘要

ABSTRACT Leveraging Metagenomics of the Microbiome to Predict Colonization/Infection by Antimicrobial- Resistant Pathogens (Project #2) Antimicrobial resistance is a growing, global threat to public health. Vancomycin-resistant enterococci (VRE), extended spectrum β-lactamase producing/carbapenem-resistant Enterobacteriaceae (ESBL-E/CRE) and Clostridiodes difficile are key antimicrobial resistant (AMR) pathogens that share the intestine as the initial site of colonization. Therefore, colonization resistance provided by the commensal microbiota of the intestines is a critical aspect of the pathophysiology of these organisms. The completion of the initial stages of the Human Microbiome Project has provided new understanding of how the microbiome impacts infections and has generated novel tools for further advances in this critical area of human health. Additionally, unbiased approaches to bacterial identification have resulted in increasing appreciation that VRE, ESBL-E/CRE, and C. difficile often co-colonize patients suggesting that these organisms are interacting with each other in addition to the commensal microflora. The long term goals of this project, in synergy with other portions of this P01 proposal, are to dissect the mechanisms underlying how interactions among the commensal microflora, the host, and VRE, ESBL-E/CRE, and C. difficile impact intestinal colonization and subsequent infection by these AMR pathogens. Although it is well known that microbiome disruption by antimicrobials is a key initial step in colonization by these pathogens, we seek to address the key knowledge gap of why only a subset of patients receiving antimicrobials become colonized and eventually infected by these organisms. To this end, we propose performing longitudinal studies of intensive care unit and hematopoietic stem cell transplant patients at two distinct hospitals in the Texas Medical Center. Patients will be classified depending on both initial and longitudinal colonization status, and these classifications will be correlated with metagenomics based microbiome analyses of serial stool samples. In concert with computational biologists, the metagenomics data will be mined for particularly species or combinations of species that are either protective against or positively associated with colonization and infection, including co-colonization. Additionally, we will test whether samples from the clinical cohort can protect mice from AMR pathogen challenge to validate associations observed clinically. Finally, we will also use animal models to test how pre-existing colonization with a particular organism under study impacts subsequent colonization by a distinct AMR pathogen. By synergizing with microbiota experts, computational biologists, and physician-scientists from the highly integrated Gulf Coast Consortium on Antimicrobial Resistance, this proposal seeks to sharpen understanding of how critical AMR pathogens colonize and infect humans in order to provide a critical platform for novel preventive or therapeutic approaches to mitigate the AMR scourge.
摘要 利用微生物组的宏基因组学预测抗菌剂的定植/感染- 耐药病原体(项目#2) 抗生素耐药性是对公共卫生日益严重的全球威胁。万古霉素耐药肠球菌(VRE), 产超广谱β-内酰胺酶/碳青霉烯类耐药肠杆菌科(ESBL-E/CRE)和 艰难梭菌是主要的耐药性(AMR)病原体,它们共享肠道作为初始位点 殖民化。因此,由肠道的肠道微生物群提供的定植抗性是一种有效的方法。 这些生物体的病理生理学的关键方面。完成人类的初始阶段 微生物组项目为微生物组如何影响感染提供了新的理解, 为人类健康这一关键领域的进一步发展创造了新的工具。此外,无偏 细菌鉴定的方法导致越来越多的人认识到VRE、ESBL-E/CRE和C. 艰难梭菌经常在患者体内共存,这表明这些生物除了与其他微生物相互作用外, 微生物群落本项目的长期目标与本P01提案的其他部分协同, 是要剖析潜在的机制,如何相互作用之间的肠道微生物区系,主机,和VRE, ESBL-E/CRE和C.艰难梭菌影响肠道定植和随后由这些AMR病原体感染。 尽管众所周知,抗微生物剂对微生物组的破坏是这些细菌定殖的关键初始步骤, 病原体,我们寻求解决关键的知识差距,为什么只有一个子集的患者接受抗菌药物 成为殖民地并最终被这些生物体感染。为此,我们建议执行纵向 对德克萨斯州两家不同医院的重症监护室和造血干细胞移植患者的研究 医学中心患者将根据初始和纵向定植状态进行分类, 这些分类将与连续粪便样品的基于宏基因组学的微生物组分析相关联。 与计算生物学家合作,宏基因组学数据将被挖掘用于特定物种或 对定植和感染具有保护作用或与定植和感染正相关的物种的组合, 包括共同殖民。此外,我们将测试来自临床队列的样本是否可以保护小鼠 从AMR病原体挑战,以验证临床观察到的关联。最后,我们还将使用动物 模型来测试预先存在的殖民与研究中的特定生物如何影响随后的 由不同的AMR病原体定殖。通过与微生物群专家、计算生物学家和 来自高度整合的墨西哥湾沿岸抗菌素耐药性联盟的医生科学家, 旨在加深对关键AMR病原体如何定殖和感染人类的理解, 一个重要的平台,用于新的预防或治疗方法,以减轻AMR祸害。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SAMUEL A SHELBURNE其他文献

SAMUEL A SHELBURNE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SAMUEL A SHELBURNE', 18)}}的其他基金

Role of β-lactamase encoding gene amplification in the development of non-carbapenemase producing, carbapenem-resistant Enterobacteriaceae
β-内酰胺酶编码基因扩增在产生非碳青霉烯酶、耐碳青霉烯肠杆菌科细菌中的作用
  • 批准号:
    10373951
  • 财政年份:
    2021
  • 资助金额:
    $ 55.34万
  • 项目类别:
Impact of regulatory cross-talk on the pathophysiology of emergent acapsular group A streptococcus
监管串扰对新出现的无荚膜 A 族链球菌病理生理学的影响
  • 批准号:
    10301505
  • 财政年份:
    2021
  • 资助金额:
    $ 55.34万
  • 项目类别:
Impact of regulatory cross-talk on the pathophysiology of emergent acapsular group A streptococcus
监管串扰对新出现的无荚膜 A 族链球菌病理生理学的影响
  • 批准号:
    10449272
  • 财政年份:
    2021
  • 资助金额:
    $ 55.34万
  • 项目类别:
Project 2: Leveraging Metagenomics of the Microbiome to predict colonization/infection by antimicrobial-resistant pathogens
项目 2:利用微生物组的宏基因组学来预测耐药病原体的定植/感染
  • 批准号:
    10226288
  • 财政年份:
    2020
  • 资助金额:
    $ 55.34万
  • 项目类别:
Project 2: Leveraging Metagenomics of the Microbiome to predict colonization/infection by antimicrobial-resistant pathogens
项目 2:利用微生物组的宏基因组学来预测耐药病原体的定植/感染
  • 批准号:
    10614694
  • 财政年份:
    2020
  • 资助金额:
    $ 55.34万
  • 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
  • 批准号:
    8300803
  • 财政年份:
    2011
  • 资助金额:
    $ 55.34万
  • 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
  • 批准号:
    8107818
  • 财政年份:
    2011
  • 资助金额:
    $ 55.34万
  • 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
  • 批准号:
    8479310
  • 财政年份:
    2011
  • 资助金额:
    $ 55.34万
  • 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
  • 批准号:
    8692634
  • 财政年份:
    2011
  • 资助金额:
    $ 55.34万
  • 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
  • 批准号:
    8871663
  • 财政年份:
    2011
  • 资助金额:
    $ 55.34万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 55.34万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 55.34万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 55.34万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 55.34万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 55.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 55.34万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 55.34万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 55.34万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 55.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 55.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了